Y
Yuan Lu
Researcher at University of Arkansas for Medical Sciences
Publications - 13
Citations - 431
Yuan Lu is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Epworth Sleepiness Scale & Obstructive sleep apnea. The author has an hindex of 7, co-authored 13 publications receiving 292 citations.
Papers
More filters
Journal ArticleDOI
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
Paula K. Schweitzer,Russell Rosenberg,Gary Zammit,Mark H. Gotfried,Dan Chen,Lawrence P. Carter,Hao Wang,Yuan Lu,Jed Black,Atul Malhotra,Kingman P. Strohl,Tones Study Investigators +11 more
TL;DR: Solriamfetol significantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most adverse events were mild or moderate in severity.
Journal ArticleDOI
A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
Michael J. Thorpy,Colin M. Shapiro,Geert Mayer,Bruce C. Corser,Helene A. Emsellem,Giuseppe Plazzi,Dan Chen,Lawrence P. Carter,Hao Wang,Yuan Lu,Jed Black,Yves Dauvilliers +11 more
TL;DR: This phase 3 study evaluated the safety and efficacy of solriamfetol in narcolepsy with a single dose of JZP‐110.
Journal ArticleDOI
Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study
Patrick J. Strollo,Jan Hedner,Nancy A. Collop,Daniel G. Lorch,Dan Chen,Lawrence P. Carter,Yuan Lu,Lawrence Lee,Jed Black,Jean-Louis Pépin,Susan Redline,Markku Partinen,Olli Polo,Tarja Saaresranta,Christine Paschen,Lena Leissner,Bradley Block,Robert C. Doekel,Stephen P. Duntley,Guillermo Giangreco,Rachel J. Givelber,Andrew D. Krystal,Chitra Lal,Mitchell Lee,James Maynard,Daniel Norman,Russell Rosenberg,Vernon Rowe,Kathleen Sarmiento,Andrew Schreiber,Richard Schwab,David Seiden,Morteza Shamsnia,J. Catesby Ware +33 more
TL;DR: This study demonstrated maintenance of solriamfetol efficacy and safety over 6 weeks and common adverse events included headache, dry mouth, nausea, dizziness, and insomnia.
Journal ArticleDOI
Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
Chad Ruoff,Todd J. Swick,Robert C. Doekel,Helene A. Emsellem,Neil T. Feldman,Russell Rosenberg,Gary Bream,Moise A. Khayrallah,Yuan Lu,Jed Black +9 more
TL;DR: At doses of 150-300 mg/day, JZP-110 was well tolerated and significantly improved the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy.
Journal ArticleDOI
Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy
Richard K. Bogan,Neil T. Feldman,Helene A. Emsellem,Russell Rosenberg,Yuan Lu,Gary Bream,Moise A. Khayrallah,D. Alan Lankford +7 more
TL;DR: The efficacy of JZP-110 for impaired wakefulness and excessive sleepiness was observed at 150-300 mg/day and as early as one week after initiating treatment (Clinicaltrials.gov identifier NCT01485770).